etravirine NDC 60219-1720

NDC codes

FDA NDC Directory

Product NDC (as listed)60219-1720Labeler and product segments. Claims need a package NDC.

Product NDC at billing width60219-1720Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
60219-1720-7	60219172007	120 TABLET in 1 BOTTLE, PLASTIC (60219-1720-7)Marketed from Jun 14, 2021

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): etravirine
Generic name (nonproprietary): etravirine
Active ingredients: Etravirine — 25 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Amneal Pharmaceuticals NY LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 214196
Marketing start: Jun 14, 2021
Listing expires: Dec 31, 2026
Other FDA classes: Cytochrome P450 2C19 Inhibitors (Mechanism)Cytochrome P450 2C9 Inhibitors (Mechanism)Cytochrome P450 3A Inducers (Mechanism)Non-Nucleoside Analog (EXT)Non-Nucleoside Reverse Transcriptase Inhibitors (Mechanism)P-Glycoprotein Inhibitors (Mechanism)
Identifiers: Product ID 60219-1720_d93c4af1-6f7d-4744-8b1e-21d89a5f5c9bSPL ID d93c4af1-6f7d-4744-8b1e-21d89a5f5c9bSPL set ID 4e009f19-4609-4020-bee1-dc27c504046cRxCUI 754761, 1052658, 1250721UNII 0C50HW4FO1UPC 0360219172074
Pharmacologic class: Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N460219172007 followed by a unit qualifier and the quantity

Package 60219-1720-07. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 25, 2025.

Indications (excerpt from the label)

Etravirine tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients and pediatric patients 2 years of age and older [see Microbiology (12.4) and Clinical Studies (14) ] . Etravirine is a human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for treatment of HIV-1 infection in treatment-experienced patients 2 years of age and older. (1)

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 214196

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 214196
Product	Strength	Form · route	Labeler	Product NDC
etravirine	Etravirine 100 mg/1	TabletOral	AvKARE	42291-473
etravirine	Etravirine 200 mg/1	TabletOral	AvKARE	42291-474
etravirine	Etravirine 100 mg/1	TabletOral	Amneal Pharmaceuticals NY LLC	60219-1721
etravirine	Etravirine 200 mg/1	TabletOral	Amneal Pharmaceuticals NY LLC	60219-1722